Julian Baker Baker Bros. Advisors
Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$71.2M |
| 2 |
BCYC
Bicycle Therapeutics
BCYC
|
+$67M |
| 3 |
Edgewise Therapeutics
EWTX
|
+$43.3M |
| 4 |
AbCellera Biologics
ABCL
|
+$23.6M |
| 5 |
Denali Therapeutics
DNLI
|
+$21.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$242M |
| 2 |
Immunocore
IMCR
|
+$69M |
| 3 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$20.9M |
| 4 |
DAWN
Day One Biopharmaceuticals
DAWN
|
+$14.6M |
| 5 |
ARS Pharmaceuticals
SPRY
|
+$11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.96% |
| 2 | Financials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Sera Prognostics
SERA
$84.4M
| $49.5M | 0.62% |
5,434,399
| – | – |
|
27
Prelude Therapeutics
PRLD
$529M
| $48M | 0.6% |
10,123,824
| – | – |
|
28
IDEAYA Biosciences
IDYA
$3.83B
| $46.6M | 0.58% |
1,062,123
| – | – |
|
29
Stoke Therapeutics
STOK
$2.08B
| $45.5M | 0.57% |
3,368,443
+1,338,309
| +66% | +$8.11M |
|
30
Xenon Pharmaceuticals
XENE
$5.88B
| $42.8M | 0.54% |
993,679
| – | – |
|
|
IGMS
31
DELISTED
IGM Biosciences
IGMS
| $39.5M | 0.49% |
4,088,322
+397,311
| +11% | +$4.6M |
|
32
Cerus
CERS
$566M
| $36.8M | 0.46% |
19,477,339
| – | – |
|
33
Monte Rosa Therapeutics
GLUE
$1.22B
| $34.7M | 0.43% |
4,916,095
| – | – |
|
34
Celcuity
CELC
$4.58B
| $33.5M | 0.42% |
1,552,478
+1,017,000
| +190% | +$16.2M |
|
35
Biomea Fusion
BMEA
$99.3M
| $31.5M | 0.4% |
2,108,949
| – | – |
|
36
Krystal Biotech
KRYS
$10.3B
| $30.2M | 0.38% |
169,934
| – | – |
|
37
Sana Biotechnology
SANA
$1.17B
| $23.8M | 0.3% |
2,380,949
+380,949
| +19% | +$2.85M |
|
38
Neurogene
NGNE
$773M
| $23.2M | 0.29% |
456,015
+2,499
| +0.6% | +$83.5K |
|
|
VERV
39
DELISTED
Verve Therapeutics
VERV
| $22.5M | 0.28% |
1,691,530
| – | – |
|
40
TScan Therapeutics
TCRX
$52.8M
| $22.1M | 0.28% |
2,784,792
| – | – |
|
|
ADAP
41
DELISTED
Adaptimmune Therapeutics
ADAP
| $17M | 0.21% |
10,787,022
-182,260
| -2% | -$220K |
|
42
Immunovant
IMVT
$9.16B
| $13.7M | 0.17% |
425,009
| – | – |
|
|
TSVT
43
DELISTED
2seventy bio
TSVT
| $13.4M | 0.17% |
2,497,526
| – | – |
|
44
Fate Therapeutics
FATE
$279M
| $13.3M | 0.17% |
+1,818,181
| New | +$11.3M |
|
45
Xencor
XNCR
$2.07B
| $12.1M | 0.15% |
545,431
+300,000
| +122% | +$6.48M |
|
46
Taysha Gene Therapies
TSHA
$1.98B
| $11.5M | 0.14% |
4,004,756
| – | – |
|
|
DBVT
47
DBV Technologies
DBVT
$914M
| $10.9M | 0.14% |
1,461,426
| – | – |
|
48
Celldex Therapeutics
CLDX
$3.17B
| $10.4M | 0.13% |
247,644
| – | – |
|
49
Relay Therapeutics
RLAY
$4.26B
| $9.63M | 0.12% |
1,160,117
| – | – |
|
50
Insmed
INSM
$27.5B
| $9.31M | 0.12% |
343,000
| – | – |
|
Similar funds
Julian Baker's Q1 2024 Portfolio in Review
As of Q1 2024, Julian Baker held 94 positions worth $7.97B, down 9.3% from $8.79B the previous quarter. Its ten largest holdings account for 77% of the portfolio.
Julian Baker's Q1 2024 filing shows 12 new, 15 increased, 7 reduced and 7 closed positions. Its largest new stake was Fate Therapeutics: 1,818,181 shares worth $13.3M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $242M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.
- Julian Baker's largest Q1 2024 buy was Fate Therapeutics: 1,818,181 shares worth $13.3M.
- Julian Baker added most to Revolution Medicines in Q1 2024, an estimated $71.2M increase.
- Julian Baker's biggest Q1 2024 reduction was Immunocore, cutting an estimated $69M.
- Julian Baker fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $242M.
- Julian Baker's ten largest holdings make up 77% of its $7.97B portfolio in Q1 2024.
- Julian Baker opened 12 new positions and closed 7 in Q1 2024.
- Julian Baker's portfolio value fell 9.3% quarter-over-quarter to $7.97B.
Based on Baker Bros. Advisors's 13F filing for Q1 2024, filed 15 May 2024.